Based on Fluxion's patented microfluidics, the IsoFlux System combines the power...
The IonFlux 16 makes automated patch clamp recordings easier and more affordable tha...
The IonFlux mercury HT is the world's highest throughput and most economical aut...
BioFlux provides a fully integrated solution for running biologically relevant cellu...
BioFlux provides a fully integrated solution for running biologically relevant cellu...
Quick Facts
- Founded: 2005
- Location: 1901 Poplar Street Suite B, Oakland CA, 94607
- Principal focus: analytical instruments for functional cell-based assays
- Key Products:
- BioFlux system for live cell analysis under shear flow
- IonFlux system for automated patch clamping
Customer Focused
Fluxion's goal is to create innovative solutions for its customers which offer superior performance, simplified workflows and cost savings over conventional assay techniques. Fluxion's customers include:
- Biotech and pharmaceutical companies - Johnson & Johnson, Pfizer, Genentech
- Leading academic institutions- Harvard, Stanford, Cornell
- Government research organizations - NIH, Walter Reed, Lawrence Berkeley
Product Development Strategy
Fluxion works closely with its customers and collaborators to develop new products and applications. The company's first two products, BioFlux and IonFlux, were the result of extensive product development and testing both internally and with leading academic and biopharmaceutical institutions.
In 2008, BioFlux 200 was the recipient of the R&D 100 Award given by R&D Magazine to the top 100 new technologies of the year.
Advanced Research and Development
In addition to its core product lines, Fluxion is also engaged in cutting-edge research to produce the next generation of breakthrough technologies. Fluxion has been awarded several research grants from the National Institutes of Health to develop platforms for critical disease research areas.
Leadership
Fluxion is led by an experienced team of professionals from the bioanalytical tool industry. The Board of Directors comprises senior executives and investors representing some of the leading biotech and technology companies in the industry.